192 365

Cited 0 times in

E1B 55kD 유전자 결손 아데노바이러스의 종양 특이 증식 및 살상능 검증.

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author노재경-
dc.date.accessioned2019-11-11T05:54:14Z-
dc.date.available2019-11-11T05:54:14Z-
dc.date.issued2000-
dc.identifier.issn0496-6872-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/172251-
dc.description.abstractPurpose: To overcome the limitations of cancer gene therapy using replication-incom- petent adenovirus, we generated E1B 55 kD-deleted adenovirus (YKL-1) by polymerase chain reaction (PCR) and homologous recombination. We then investigated tumor-specific virus replication and cytotoxicity of YKL-1 in vitro and in vivo. Materials and Methods: YKL-1 was constructed by reintroducting E1A and E1B 19 kD into pTG-CMV El/E3-deficient adenoviral vector and inducing homologous recombination in E. coli. The recombinant vector pYKL-1 was transfected into 293 cells to generate YKL-1. The properties of newly constructed YKL-1 was defined by PCR and immuno- blotting analysis. Virus replication was examined by infecting human normal and cancer cells on 6-wells at multiplicity of infection (MOI) of 10 for 3 days. Virus was then recovered and titered. Cytopathic effect was analyzed by infecting human normal and cancer cells on 24-wells at MOIs of 10, 1 or 0.1 for 7 to 10 days and staining them with crystal violet solution. Inhibition of tumor growth was examined in human cancer cell xenografts in nu/nu mice by intratumoral injection of YKL-l. Results: PCR and immunoblotting analysis confirmed that YKL-1 contained E1A and E1B 19 kD but not E1B 55 kD. In human normal cells, virus replication and subsequent cytopathic effect of E1B 55 kD-deleted adenovirus YKL-1 was markedly attenuated by larger than 2 to 3 log in magnitude, compared to that of wild-type ad-XJ. In contrast, YKL-1 was capable of replicating and inducing cytotoxicity i.n most human cancer cells. C33A and Hep3B containing p53 mutation were much more sensitive, whereas HeLa and H460 with wild type p53 were relatively resistant to YKL-1. Finally, the tumor growth was dramatically retarded by intratumoral injection of YKL-1 in C33A cervical cancer xenograft and the histology showed significant necrosis by intratumoral injection of YKL-1. Conclusion: The results here demonstrated the ability of preferential virus replication and cytotoxicity of ElB 55 kD-deleted adenovirus YKL-1 in human cancer cells. Therefore, these indicated a promising potential of YKL-1 as an antitumoral virus agent and a selective replication-competent virus vector.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한암학회-
dc.relation.isPartOfJournal of the Korean Cancer Association (대한암학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleE1B 55kD 유전자 결손 아데노바이러스의 종양 특이 증식 및 살상능 검증.-
dc.title.alternativeTumor-specific Virus Replication and Cytotoxicity of E1B 55 kD-deleted Adenovirus-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthor김재성-
dc.contributor.googleauthor이보영-
dc.contributor.googleauthor김진안-
dc.contributor.googleauthor안중배-
dc.contributor.googleauthor박준오-
dc.contributor.googleauthor유내춘-
dc.contributor.googleauthor김주항-
dc.contributor.googleauthor노재경-
dc.contributor.googleauthor민진식-
dc.contributor.googleauthor김병수-
dc.contributor.googleauthor이희란-
dc.contributor.localIdA00945-
dc.contributor.localIdA01290-
dc.relation.journalcodeJ01813-
dc.subject.keywordAdenovirus-
dc.subject.keywordGene therapy-
dc.subject.keywordEl gene-
dc.subject.keywordpS3 gene-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.affiliatedAuthor김주항-
dc.contributor.affiliatedAuthor노재경-
dc.citation.volume32-
dc.citation.number1-
dc.citation.startPage200-
dc.citation.endPage209-
dc.identifier.bibliographicCitationJournal of the Korean Cancer Association (대한암학회지), Vol.32(1) : 200-209, 2000-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.